Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals Inc.

In a report released yesterday, William Wood from B. Riley Securities maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $...

Madrigal Pharmaceuticals (MDGL) Receives a Buy from B. Riley Securities

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Madrigal Pharmaceuticals. The company’s shares cl...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MDGL	$547.96	+1.08%	567.23K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MDGL	$547.96	+1.1%	567.23K
3
4
5
6

MDGL

MDGL

Get Madrigal Pharmaceuticals Inc. Data in Excel

Get Madrigal Pharmaceuticals Inc. Data in Excel